An Introduction to Cardiovascular Risk
Despite substantial treatment advances, cardiovascular diseases (CVDs) remain the leading cause of death in the world. Recent research has revealed that nearly seven in ten cases of CVD can be explained by modifiable risk factors: such as high blood pressure, abdominal obesity, low education, smoking, dyslipidaemia, poor diet, strength and physical activity, diabetes, depression, and air pollution. Diagnosis and management of these risk factors are essential to preventing premature deaths due to CVD. However, there remains a significant risk of cardiovascular events despite optimal risk factor management. Other less understood, potentially modifiable risk factors include inflammatory, pro-thrombotic and metabolic pathways, and warrant further study.
Browse our gallery of video highlights and short articles from the conference hub, providing the latest expert insights from major conferences and peer-reviewed articles from the journal portfolio.
Cardiovascular Risk Content
Addressing cardiorenal outcomes in CKD and T2D: What are the key considerations for daily practice?
Watch experts in endocrinology and in primary care discuss key considerations for addressing cardiorenal outcomes in patients with CKD/T2D
- Identify the epidemiological and pathophysiological drivers behind the progression of CKD
- Recognize the specific renal and cardiovascular risks associated with CKD and T2D and the therapies available to address them
- Apply the latest clinical guidelines to treating patients with CKD and T2D in daily practice
Latest guidelines, novel therapies and emerging options for managing dyslipidemias and ASCVD risk in daily practice
Watch cardiology experts discuss how the latest guidelines and treatments are applied to reduce ASCVD risk in patients with dyslipidemias
- Choose appropriate lipid goals for patients with dyslipidemias and at risk of ASCVD, considering the latest guidelines
- Formulate guideline-based and forward-thinking strategies to reduce ASCVD risk in patients with dyslipidemias using appropriate lipid- and lipoprotein-lowering therapies
- Recognize special populations of patients with dyslipidemias and apply important considerations when treating them with lipid- and lipoprotein-lowering therapies
Siddharth Patel, ESC 2022: P2Y12 inhibition with ticagrelor in patients with higher lipoprotein A, the PEGASUS-TIMI 54 trial insights
With insights from the PEGASUS-TIMI 54 study, it was assessed whether patients with higher lipoprotein A treated with ticagrelor, a P2Y12 inhibitor, have a greater reduction in cardiovascular risk. In this touchCARDIO interview, we speak with Dr Siddharth Patel (Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA) to discuss the role of lipoprotein […]
Michael Miller, ESC 2022: A post hoc analysis of REDUCE-IT, the effect of icosapent ethyl on cardiovascular risk in smoking
With effective treatment currently limited to smoking cessation, REDUCE-IT aimed to evaluate the effects of icosapent ethyl on cardiovascular risk in patients with a history of smoking. In this touchCARDIO interview, we speak with Dr Michael Miller (Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA) to discuss the post hoc analysis of REDUCE-IT […]
Michael Miller, ESC 2022: Icosapent ethyl for smoking, the REDUCE-IT study
The REDUCE-IT study evaluated the effects of icosapent ethyl on cardiovascular risk in patients with a history of smoking. In this touchCARDIO interview, we speak with Dr Michael Miller (Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA) to discuss the REDUCE-IT study and n–3 fatty acid supplementation. The abstract entitled ‘Icosapent Ethyl diminishes […]
Filipe Moura, ESC 2022: A post-hoc analysis of the DECLARE-TIMI 58 and DAPA-CKD trials of dapagliflozin in patients with type 2 diabetes
Combining data from the DECLARE and DAPA-CKD trials enables the effect of dapagliflozin to be examined across a spectrum of baseline kidney function. In this touchCARDIO interview, we speak with Dr Filipe Moura (Brigham and Women’s Hospital, Harvard Medical School, Boston, USA) to discuss the post-hoc analysis of the DECLARE and DAPA-CKD data and the […]
Filipe Moura, ESC 2022: Dapagliflozin in the DECLARE-TIMI 58 and DAPA-CKD trials for patients with type 2 diabetes
Dapagliflozin is a sodium glucose co-transporter 2 inhibitor that was studied in the DECLARE-TIMI 58 and DAPA-CKD trials. In this touchCARDIO interview, we speak with Dr Filipe Moura (Brigham and Women’s Hospital, Harvard Medical School, Boston, USA) to discuss the lessons from the DECLARE and DAPA-CKD trials about dapagliflozin’s impact on cardiovascular and renal events. […]
Problems that occur when varicose veins go untreated
Dr Yan Katsnelson, Founder, CEO, USA Vein Clinics Dr Yan Katsnelson is an entrepreneur, highly skilled cardiac surgeon, business owner, and philanthropist. He is the founder and CEO of USA Vein Clinics, which is part of USA Clinics Group – the parent company of USA Fibroid Centers, USA Vascular Centers, and USA Oncology Centers. Dr […]
Dylan Steen, ACC 2022: SuperWIN: A multisite randomized, controlled trial of a supermarket and web-based intervention targeting nutrition for cardiovascular risk reduction
The SuperWIN study is a supermarket and web-based intervention targeting nutrition. touchCARDIO spoke to Prof Dylan Steen (University of Cincinnati Medical Center, Cincinnati, OH, USA) to discuss his presentation at the American College of Cardiology Annual Meeting 2022 entitled ‘SuperWIN: A Multisite, Randomized, Controlled Trial of a Supermarket and Web-based Intervention Targeting Nutrition For Cardiovascular […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!